Correlation Between Immunome and Aerovate Therapeutics

Can any of the company-specific risk be diversified away by investing in both Immunome and Aerovate Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Immunome and Aerovate Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Immunome and Aerovate Therapeutics, you can compare the effects of market volatilities on Immunome and Aerovate Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Immunome with a short position of Aerovate Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Immunome and Aerovate Therapeutics.

Diversification Opportunities for Immunome and Aerovate Therapeutics

0.34

Correlation Coefficient

Immunome  Aerovate Therapeutics

Weak diversification

The 3 months correlation between Immunome and Aerovate is 0.34. Overlapping area represents the amount of risk that can be diversified away by holding Immunome and Aerovate Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Aerovate Therapeutics and Immunome is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Immunome are associated (or correlated) with Aerovate Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Aerovate Therapeutics has no effect on the direction of Immunome i.e., Immunome and Aerovate Therapeutics go up and down completely randomly.

Pair Corralation between Immunome and Aerovate Therapeutics

Given the investment horizon of 90 days Immunome is expected to generate 2.78 times more return on investment than Aerovate Therapeutics. However, Immunome is 2.78 times more volatile than Aerovate Therapeutics. It trades about 0.06 of its potential returns per unit of risk. Aerovate Therapeutics is currently generating about -0.07 per unit of risk. If you would invest  933.00  in Immunome on November 20, 2024 and sell it today you would earn a total of  107.00  from holding Immunome or generate 11.47% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Immunome  vs.  Aerovate Therapeutics

Immunome

Risk-Adjusted Performance

Insignificant

Compared to the overall equity markets, risk-adjusted returns on investments in Immunome are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. In spite of very weak basic indicators, Immunome displayed solid returns over the last few months and may actually be approaching a breakup point.

Aerovate Therapeutics

Risk-Adjusted Performance

Very Weak

Over the last 90 days Aerovate Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest fragile performance, the Stock's basic indicators remain sound and the latest tumult on Wall Street may also be a sign of longer-term gains for the firm shareholders.

Pair Trading with Immunome and Aerovate Therapeutics

The main advantage of trading using opposite Immunome and Aerovate Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Immunome position performs unexpectedly, Aerovate Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Aerovate Therapeutics will offset losses from the drop in Aerovate Therapeutics' long position.

The idea behind Immunome and Aerovate Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.